Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Keith T. Flaherty, Mario Mandalà et al.|The Lancet Oncology|2018Cited by 1k
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|The Lancet Oncology|2018Cited by 586